Clipped this from Yahoo IPIC thread:
"bucindolol
Last Updated: 30th March 1998
Highest Dev. Status: Phase 3 Clinical
Indication: Cardiac failure, Heart disease, Hypertension
Action: Beta adrenoceptor antagonist
Summary
Bucindolol is a beta 1 and 2 adrenoceptor antagonist under development by Intercardia as a potential treatment for hypertension and congestive heart failure. Astra/Merck, Intercardia, Knoll AG and the NIH are conducting phase III trials for these indications. The compound originated with Bristol Myers Squibb, which licensed the drug to CPEC, which was subsequently taken over by Intercardia.
Bucindolol is being tested in the phase III Beta-blocker Evaluation of Survival Trial (BEST), which began in June 1995 by the National Institutes of Health and the Veterans Administration for congestive heart failure (CHF). The study will include 2,800 patients and is being funded by the US National Institutes of Health (NIH), the Department of Veterans Affairs and with a $2 million contribution from Intercardia.
The compound is also in phase III trials with Astra for the treatment of hypertension.
Intercardia has entered into an agreement with SkyePharma's drug delivery subsidiary Jago Pharma, to develop a once-daily formulation of bucindolol. The formulation will use Jago Pharma's Geomatrix oral controlled release technology (qv).
Intercardia is a subsidiary of Interneuron formed to acquire 80% of Cardiovascular Pharmacology and Engineering Consultants (CPEC) which includes the rights to bucindolol. CPEC was founded by researchers who had studied bucindolol in CHF for Bristol-Myers Squibb (BMS). BMS ceased development of the compound in 1989 and licensed it to CPEC.
Intercardia and Knoll have signed a collaborative development agreement for territories outside the US and Japan.
Development History
Developer Country Status Indication Date
National Institutes of Health US C3 Cardiac failure 01-JUN-95
Intercardia Inc US C3 Heart disease 01-JUN-95
Intercardia Inc US C3 Cardiac failure 01-JUN-95
Cardiovasc Pharmacol Eng Consultants Inc US C3 Heart disease 01-JUN-95
Bristol-Myers Squibb Co US DX Cardiac failure 01-DEC-89
Astra/Merck Inc US C3 Heart disease 01-DEC-95
Astra/Merck Inc US C3 Cardiac failure 01-DEC-95
Astra/Merck Inc US C3 Hypertension 12-NOV-97
Jago Pharm AG Switzerland DR Cardiac failure 03-APR-97
Knoll AG Germany C3 Hypertension 01-JUN-95
Licensing
Name Summary
Astra/Merck Inc Intercardia and Astra Merck are collaborating in the development and marketing of bucindolol as a treatment for moderate to severe congestive heart failure. Astra Merck made an initial payment of US$5 million to Intercardia and milestone payments will also be made. Both will share the initial marketing costs in the US and Astra Merck will market the product in return for royalties paid to Intercardia.
Knoll AG Development and commercialization of bucindolol outside the US and Japan.
In January 1997, Knoll signed a development and commercialization agreement with Intercardia.
Intercardia Inc Intercardia, a subsidiary of Interneuron, was formed to acquire 80% of Cardiovascular Pharmacology and Engineering Consultants, including the rights to bucindolol licensed from Bristol-Myers Squibb.
In January 1997, Intercardia signed a development and commercialization agreement with Knoll Jago Pharm AG Intercardia has entered into an agreement with SkyePharma's drug delivery subsidiary Jago Pharma, to develop a once daily formulation of bucindolol. The formulation will use Jago Pharma's Geomatrix oral controlled release technology (qv)." |
